Biomarkers of Renal Tumors: the Current State and Clinical Perspectives

Renal cell carcinoma (RCC) ranks the first death rate among the urogenital tumors, whereas its incidence follows the incidences of prostate and bladder cancer. The diagnosis of RCC at early stages allows immediately undertaking appropriate treatment, which significantly increases patients’ survival...

Full description

Saved in:
Bibliographic Details
Published in:Current urology reports 2017, Vol.18 (1), p.3-3, Article 3
Main Authors: Golovastova, Marina O., Korolev, Dmitry O., Tsoy, Larisa V., Varshavsky, Vladimir A., Xu, Wan-Hai, Vinarov, Andrey Z., Zernii, Evgeni Yu, Philippov, Pavel P., Zamyatnin, Andrey A.
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - analysis
Carcinoma, Renal Cell - chemistry
Carcinoma, Renal Cell - diagnosis
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - pathology
Humans
Kidney Diseases (G Ciancio
Kidney Neoplasms - chemistry
Kidney Neoplasms - diagnosis
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Male
Medicine
Medicine & Public Health
Nephrology
Prognosis
Section Editor
Survival Rate
Topical Collection on Kidney Diseases
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Renal cell carcinoma (RCC) ranks the first death rate among the urogenital tumors, whereas its incidence follows the incidences of prostate and bladder cancer. The diagnosis of RCC at early stages allows immediately undertaking appropriate treatment, which significantly increases patients’ survival rate. Early and accurate diagnosis avoids inadequate treatment, provides the disease progression forecast, and permits to apply more efficient therapy. Unfortunately, the small renal tumors are usually asymptomatic resulting in the late diagnosis and, therefore, low efficacy of treatment. Thus, sensible and preventive biomarkers are essential for early RCC detection and monitoring of its progression. So far, many attempts were performed aimed at recognizing novel informative kidney tumor biomarkers applicable for early detection of the disease and possessing prognostic and predictive capabilities. This review summarizes recent advances in renal tumor biomarkers recognition, their diagnostic and prognostic values, and clinical feasibility.
ISSN:1527-2737
1534-6285
DOI:10.1007/s11934-017-0655-1